DataMeds Regains Compliance With NASDAQ Listing Standards
Key Highlights
- ➤DataMeds AI (MEDS) regained Nasdaq equity-rule compliance on October 19, 2026
- ➤Stockholders’ equity exceeded the required $2.5 million threshold
- ➤Nasdaq previously confirmed DataMeds regained minimum $1.00 bid-price compliance
- ➤Failure to evidence compliance in its next periodic report may trigger delisting
TAMPA, FL / ACCESS Newswire / October 20, 2026 / DataMeds AI, Inc. (NASDAQ:MEDS) ("DataMeds AI," "DataMEDS SI," "DataMEDS," or the "Company"), a healthcare company leveraging its Health IT and physical infrastructure together with its super intelligence (artificial intelligence) platform EinsteinRx™ and smart contracts platform PharmacyChain™, today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated October 19, 2026, informing DataMEDS that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, DataMEDS needed to have a minimum stockholders' equity of $2.5 million.
The Company originally received a notice of delisting from NASDAQ on April 13, 2026 outlining the basis for delisting proceedings:
Get started
Create a free account to read the full story.